

IN THE SPECIFICATION:

Please amend the specification as follows:

Please replace paragraph [0001] with the following paragraph:

[0001] This application is a Divisional of U.S. Serial No. 09/706,540 filed November 4, 2000, now U.S. Patent No. 6,689,753, issued February 10, 2004, which claims priority from U.S. Provisional Application No. 60/163,911, which was filed on November 5, 1999.


Please replace the paragraph under the Abstract heading with the following paragraph:

ABSTRACT

~~The present invention is an inhibitory peptide capable of inhibiting β pleated sheet formation in amyloid β peptide. The inhibitory peptide is a β sheet breaker peptide analog designed by chemical modification of a β sheet breaker peptide capable of inhibiting β pleated sheet formation in amyloid β peptide.~~


~~The present invention also includes an inhibitory peptide capable of inhibiting conformational changes in prion PrP protein associated with amyloidosis. The inhibitory peptide being a β sheet breaker peptide analog designed by chemical modification of a β sheet breaker peptide capable inhibiting said conformational changes in prion PrP protein associated with amyloidosis.~~

In addition, the present invention includes a peptide mimetic with the following structure:




PMiA β 5

In another embodiment, the peptide mimetic has the following structure:



PMiPrP13

In yet another embodiment, the peptide mimetic has the following structure:



PMiPrP5

The present invention provides peptide analogs and peptide mimetics that inhibit pleated sheet formation in amyloid β -peptide, pharmaceutical compositions thereof and their therapeutic use. The inhibitory peptides possess activity as inhibitors in the formation of amyloid-like deposits and are useful in the treatment of Alzheimer's Disease.